Gout - Articles and news items

AstraZeneca licenses gout drug Zurampic to Grünenthal

Industry news / 2 June 2016 / Victoria White, Digital Content Producer

Grünenthal has entered into a licensing agreement with AstraZeneca for the exclusive rights to Zurampic (lesinurad) in Europe and Latin America…

AstraZeneca and Ironwood sign Zurampic licensing agreement

Industry news / 26 April 2016 / Victoria White, Digital Content Producer

Under the terms of the agreement, Ironwood Pharmaceuticals will acquire exclusive US rights to Zurampic from AstraZeneca…


AstraZeneca announces top-line results from the Phase III programme of lesinurad in combination with xanthine oxidase inhibitors in gout patients

Industry news / 14 August 2014 / AstraZeneca

AstraZeneca announced positive top-line results from CLEAR1, CLEAR2 and CRYSTAL, the pivotal Phase III clinical trials investigating the potential of lesinurad…


AstraZeneca to acquire Ardea Biosciences for $1 billion (net of existing cash)

Industry news / 23 April 2012 / AstraZeneca

Deal includes lead product lesinurad in Phase III development for gout…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...